A detailed history of Lynch Asset Management, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Lynch Asset Management, Inc. holds 45,850 shares of ABBV stock, worth $7.61 Million. This represents 3.93% of its overall portfolio holdings.

Number of Shares
45,850
Previous 47,350 3.17%
Holding current value
$7.61 Million
Previous $7.34 Million 13.79%
% of portfolio
3.93%
Previous 4.21%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024

SELL
$159.82 - $182.1 $239,730 - $273,150
-1,500 Reduced 3.17%
45,850 $8.35 Million
Q4 2023

Jan 26, 2024

SELL
$137.6 - $154.97 $68,800 - $77,485
-500 Reduced 1.04%
47,350 $7.34 Million
Q3 2023

Oct 25, 2023

SELL
$133.59 - $154.65 $333,975 - $386,625
-2,500 Reduced 4.97%
47,850 $7.13 Million
Q2 2023

Jul 17, 2023

SELL
$132.51 - $164.9 $66,255 - $82,450
-500 Reduced 0.98%
50,350 $6.78 Million
Q4 2021

Feb 02, 2022

BUY
$107.43 - $135.93 $5.46 Million - $6.91 Million
50,850 New
50,850 $6.89 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $293B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Lynch Asset Management, Inc. Portfolio

Follow Lynch Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynch Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Lynch Asset Management, Inc. with notifications on news.